When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 21 Apr 2025
Last updated: 23 Apr 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors

Other diagnostic factors

  • altered mental status
  • headache
  • nausea and/or vomiting
  • gait abnormality
  • ataxia
  • weakness
  • seizures
  • visual disturbances
  • speech deficit
  • aphasia/dysphasia
  • sensory deficit
  • motor weakness
  • visual change
  • cranial nerve palsy
  • papilloedema
  • personality change/emotional lability

Risk factors

  • white ancestry
  • male sex
  • neurofibromatosis type 1
  • tuberous sclerosis complex
  • Li-Fraumeni syndrome
  • Turcot's cancer syndrome
  • ionising radiation

Diagnostic investigations

1st investigations to order

  • MRI head
  • ophthalmological evaluation; visual field testing
  • CT head
  • brain MR spectroscopy
  • brain perfusion MRI
  • histopathology
  • molecular analyses

Investigations to consider

  • pituitary hormones tests
  • diffusion tensor imaging (DTI)

Emerging tests

  • 2-hydroxyglutarate-targeted magnetic resonance spectroscopy

Treatment algorithm

Contributors

Authors

L. Nicolas Gonzalez Castro, MD, PhD

Instructor in Neurology

Center for Neuro-Oncology

Dana-Farber Cancer Institute and Brigham and Women's Hospital

Harvard Medical School

Boston

MA

Disclosures

LNGC has received consulting fees from Elsevier, Oakstone Publishing, and Teladoc. LNGC has received research funding from Merck & Co. (to Dana-Farber Cancer Institute). LNGC is an author of a number of references cited in this topic.

Acknowledgements

Dr L. Nicolas Gonzalez Castro would like to gratefully acknowledge Dr Timothy C. Ryken, Dr Linton T. Evans, Dr Manmeet S. Ahluwalia, Dr Susan Chang, and Dr Karine Michaud, previous contributors to this topic.

Disclosures

TCR is an author of a number of references cited in this topic. MSA has acted as a consultant for Elekta, Incyte, AstraZeneca, Novocure, Caris Life Sciences, Bristol-Myers Squibb, Monteris Medical, AbbVie, MRI Solutions, Elsevier, and Prime oncology. MSA has received clinical trial investigations grants from Tracon, Bristol-Myers Squibb, AstraZeneca, Novartis, and Novocure. SC has received research support from Agios, Novartis, Quest, Roche, and Schering Plough. KM and LTE declare that they have no competing interests.

Peer reviewers

David A. Reardon, MD

Associate Professor

The Preston Robert Tisch Brain Tumor Center

Duke University Medical Center

Durham

NC

Disclosures

DAR declares that he has no competing interests.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Full text

Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021 Mar;18(3):170-86.Full text  Abstract

Liau LM. Guidelines for newly diagnosed glioblastoma. J Neurooncol. 2008 Sept;89(3).Full text

American Association of Neurological Surgeons; Congress of Neurological Surgeons. Updated AANS/CNS guidelines for progressive glioblastoma patients. Jun 2022 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available here.

Use of this content is subject to our disclaimer